Zhou Peng, Huang Jinling, Ding Wanxue
Department of Integrated Traditional Chinese and Western Medicine, Anhui University of Chinese Medicine Hefei 230012 People's Republic of China
Research Institute of Integrated Traditional Chinese and Western Medicine, Anhui Academy of Chinese Medicine Hefei 230012 People's Republic of China.
RSC Adv. 2018 Oct 22;8(63):35981-35988. doi: 10.1039/c8ra07153e.
Using traditional Chinese medicine formula Ling-Gui-Zhu-Gan decoction (LGZGD) plus selective β-adrenergic receptor inhibitor metoprolol to treat arrhythmia of coronary heart disease can significantly improve efficiency with no adverse reactions. However, the effect of major components of LGZGD on the plasma protein binding of metoprolol is unclear. Firstly, this study aimed to computationally predict the molecular interactions between metoprolol, the major components of LGZGD, and bovine serum albumin (BSA). Secondly, the plasma protein binding of metoprolol combined with major components of LGZGD was investigated by UPLC analysis coupled with ultrafiltration. The MOE (2008.10) software package was used to investigate the molecular interactions among metoprolol, the major components of LGZGD, and BSA. Using experiments, BSA was separately spiked with a mixtures of metoprolol and the major components of LGZGD. The results showed that metoprolol interacted with BSA mainly through arene-arene interactions, as did cinnamic acid and liquiritin. However, the energy scores of cinnamic acid and liquiritin were lower than that of metoprolol. There were no interactions between metoprolol and the major components of LGZGD. Further studies showed that the presence of the major components of LGZGD did not change the plasma protein binding of metoprolol. We adopted molecular docking to predict the drug-herb plasma protein binding interactions of metoprolol and then used ultrafiltration to verify the docking results. There were no drug-herb interactions between metoprolol and LGZGD in BSA, which indicated that this combination therapy might be safe and feasible.
采用中药方剂苓桂术甘汤(LGZGD)加选择性β-肾上腺素能受体抑制剂美托洛尔治疗冠心病心律失常可显著提高疗效且无不良反应。然而,LGZGD主要成分对美托洛尔血浆蛋白结合的影响尚不清楚。首先,本研究旨在通过计算预测美托洛尔、LGZGD主要成分与牛血清白蛋白(BSA)之间的分子相互作用。其次,采用超高效液相色谱(UPLC)分析结合超滤法研究美托洛尔与LGZGD主要成分结合后的血浆蛋白结合情况。使用MOE(2008.10)软件包研究美托洛尔、LGZGD主要成分与BSA之间的分子相互作用。通过实验,将美托洛尔与LGZGD主要成分的混合物分别加入BSA中。结果表明,美托洛尔与BSA主要通过芳烃-芳烃相互作用,肉桂酸和甘草苷也是如此。然而,肉桂酸和甘草苷的能量得分低于美托洛尔。美托洛尔与LGZGD主要成分之间没有相互作用。进一步研究表明,LGZGD主要成分的存在并未改变美托洛尔的血浆蛋白结合。我们采用分子对接预测美托洛尔的药物-草药血浆蛋白结合相互作用,然后用超滤法验证对接结果。在BSA中,美托洛尔与LGZGD之间不存在药物-草药相互作用,这表明这种联合治疗可能是安全可行的。